Before You Inject Peptides, Watch This — 16 Years of Clinical Reality

The FDA just voted to legalize six peptides for compounding. The pharmaceutical industry is fighting back hard. And somewhere in the middle of all that political noise are the clinicians — like Stark's own Dr. Alice — who have been using these compounds quietly, carefully, and effectively for nearly two decades. Here's what 16 years of real clinical practice actually looks like.

The Information Most People Don't Have

Peptides aren't new. They aren't fringe. And they're not something you should be ordering online and self-administering without a clinician who actually understands the steroid pathway, your DEXA data, your hormonal profile, and your specific goals. I say this as someone who, at a party last year, told a friend asking about my peptide stack: "None." He was shocked. And I meant it — because I have Dr. Alice, and I trust her read of the data over my own enthusiasm.

Dr. Alice Nguyen is Stark's Medical Lead and an NMD with a decade of clinical practice. Her first exposure to peptides was 16 years ago, before most people had even heard the word. Her early experiences with melanotan, GLP-1s, growth hormone-releasing peptides, and BPC-157 inform how Stark's clinical protocols are built — with a level of nuance that the consumer internet cannot replicate.

What GLP-1s Are Actually Doing to Lean Mass

The reason Stark hasn't adopted GLP-1s as a blanket therapy — despite the cultural obsession with semaglutide and tirzepatide — is the DEXA scan. Our data shows what happens when someone loses 25–30 pounds on a GLP-1 without the right protein intake, strength training, and hormonal support: the lean mass loss is staggering. For a woman, losing 10 pounds of muscle mass could take a decade to rebuild — even with optimal nutrition, training, and hormones all working together.

But that same story has a different version. A male student lost 25 pounds of fat and actually gained lean mass on a GLP-1 — because he was eating 200 grams of protein daily, doing high-quality strength training, and on TRT. It wasn't the GLP-1 alone. It was the full system. That's the Stark model. Not a single lever. A coordinated protocol.

The Peptides Worth Understanding

Dr. Alice's clinical hierarchy after 16 years: growth hormone-releasing peptides like Tesamorelin are now her first choice for visceral fat reduction in off-label cases — there's more human trial data on Tesamorelin than nearly any other growth hormone peptide, largely because of its FDA-approved use in HIV-related lipodystrophy. BPC-157 and TB-500 remain useful for injury recovery in injectable and liposomal forms — with the honest caveat that results vary significantly by patient, and some cases produce exceptional outcomes while others produce none.

And then there's Mots-c — a peptide released naturally during exercise that some consumers have begun self-injecting. Two Stark patients who used it ended up in the hospital with severe chest pain. That's the reality of the frontier. Some peptides we understand well. Some we're still learning. And a clinician who doesn't know that distinction cannot safely navigate it for you.

The closing thought I'll leave you with is this: the prescription and management of peptides is nearly as individualized as hormone replacement therapy for women — which is the most personalized medicine we practice. If you're working with a clinician who treats peptides like a vending machine, you're missing the most important variable. The variable is you — your labs, your DEXA, your hormonal baseline, your goals. That context is everything.

At Stark, we measure first. Then we build. That's health optimization for business leaders in Newport Beach and Tustin who are willing to invest in doing it right.